Hospital
Children's Hospital
Children's Hospital was paid $150.93M by Medicaid between Jan 2018 and Dec 2024, across 336 billing codes. Its largest line is 99283, emergency room visit (moderate) — 34% of everything it billed.
33Billing provider infoCHILDREN'S HOSPITAL
NEW ORLEANS, LA 70118
NEW ORLEANS, LA 70118
33aNPI1104819366assigned 08/23/2005
33bProvider typeChildren's Hospital
28Total paid$150.93M
24GClaims1,583,325
24DCodes billed336
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 159,451 | $9.88M | |
| 2019 | 169,746 | $12.49M | |
| 2020 | 135,639 | $8.65M | |
| 2021 | 239,447 | $19.38M | |
| 2022 | 304,058 | $32.53M | |
| 2023 | 322,757 | $35.48M | |
| 2024incomplete | 252,227 | $32.51M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 34% | 132,532 | 119,993 | $51.32M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 57,367 | 51,992 | $28.76M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.5% | 19,306 | 16,713 | $11.28M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 6.4% | 281,939 | 255,601 | $9.63M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 5.7% | 171,521 | 157,019 | $8.58M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.1% | 15,463 | 14,517 | $4.72M |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2.6% | 47,518 | 42,448 | $3.93M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 2.1% | 107,167 | 99,110 | $3.17M |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 1.8% | 53,771 | 49,353 | $2.70M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.5% | 64,956 | 57,158 | $2.33M |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.1% | 6,393 | 5,510 | $1.65M |
| 41899 | Unlisted procedure, dentoalveolar structures | 1.0% | 2,632 | 2,273 | $1.57M |
324 more codes
| 93325 | <1% | 6,068 | $1.30M | |
| 72082 | <1% | 5,758 | $1.19M | |
| G0378 | Hospital observation service, per hour | <1% | 1,599 | $1.16M |
| 92551 | <1% | 25,257 | $817K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 10,840 | $788K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 27,488 | $787K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 23,912 | $735K |
| 29705 | <1% | 4,281 | $671K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,999 | $633K |
| 92587 | <1% | 5,210 | $589K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 1,861 | $511K |
| 54161 | <1% | 1,865 | $452K | |
| 92567 | <1% | 5,338 | $428K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 28,153 | $379K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 406 | $372K |
| 80053 | Comprehensive metabolic panel | <1% | 35,398 | $354K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 8,179 | $349K |
| 94010 | <1% | 1,684 | $346K | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 4,018 | $334K |
| 64642 | <1% | 1,273 | $332K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 4,502 | $308K |
| 94060 | <1% | 994 | $299K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 35,978 | $246K |
| 76770 | <1% | 1,082 | $246K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 2,151 | $239K |
| 95012 | <1% | 2,914 | $238K | |
| 86003 | <1% | 2,893 | $237K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 601 | $230K |
| 87634 | <1% | 3,361 | $207K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 71,761 | $192K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,194 | $186K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 1,647 | $186K |
| 90999 | Dialysis (unlisted procedure) | <1% | 717 | $185K |
| 94664 | <1% | 1,364 | $182K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 19,213 | $180K |
| 54150 | <1% | 506 | $176K | |
| 93321 | <1% | 652 | $175K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 892 | $173K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 6,330 | $172K |
| 72020 | <1% | 1,573 | $171K | |
| 17110 | <1% | 1,004 | $167K | |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 458 | $146K |
| 92060 | <1% | 1,515 | $136K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 10,360 | $117K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 298 | $113K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 4,868 | $113K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,784 | $113K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 7,342 | $108K |
| 93320 | <1% | 481 | $100K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 635 | $92K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,082 | $91K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 102 | $89K |
| 83655 | <1% | 7,171 | $86K | |
| 94760 | <1% | 3,441 | $80K | |
| 74018 | <1% | 732 | $79K | |
| 93304 | <1% | 266 | $74K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 798 | $68K |
| 86756 | <1% | 4,761 | $66K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 4,067 | $65K |
| 76825 | <1% | 324 | $64K | |
| 95816 | <1% | 249 | $62K | |
| 76827 | <1% | 336 | $62K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 388 | $61K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,019 | $61K |
| 73630 | <1% | 650 | $59K | |
| 95951 | <1% | 58 | $58K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,985 | $52K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,271 | $52K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,151 | $50K |
| 84439 | <1% | 6,000 | $50K | |
| 96138 | <1% | 723 | $50K | |
| 96132 | <1% | 866 | $50K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 574 | $49K |
| 86235 | <1% | 1,085 | $48K | |
| 71045 | Radiologic examination, chest; single view | <1% | 516 | $46K |
| 92650 | <1% | 361 | $46K | |
| 94726 | <1% | 148 | $44K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 239 | $43K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 749 | $42K |
| 82728 | <1% | 3,459 | $41K | |
| 82784 | <1% | 2,200 | $39K | |
| 87486 | <1% | 1,141 | $39K | |
| 87581 | <1% | 1,137 | $39K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,736 | $39K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,470 | $38K |
| 85018 | <1% | 15,369 | $37K | |
| 96127 | <1% | 3,808 | $36K | |
| 86317 | <1% | 1,031 | $35K | |
| 72170 | <1% | 240 | $34K | |
| 87081 | <1% | 5,486 | $31K | |
| 0071A | <1% | 922 | $31K | |
| 80050 | General health panel | <1% | 846 | $30K |
| 0072A | <1% | 738 | $28K | |
| 73610 | <1% | 381 | $28K | |
| 73564 | <1% | 161 | $27K | |
| 81003 | <1% | 12,834 | $26K | |
| 76820 | <1% | 100 | $26K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 787 | $26K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 788 | $25K |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 144 | $25K |
| 92557 | <1% | 211 | $24K | |
| 0002A | <1% | 817 | $24K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 727 | $23K |
| 73100 | <1% | 246 | $22K | |
| 81025 | <1% | 3,443 | $20K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 72 | $20K |
| 80061 | Lipid panel | <1% | 1,802 | $20K |
| 42830 | <1% | 35 | $20K | |
| 70486 | <1% | 45 | $20K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 21 | $19K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,939 | $19K |
| 70360 | <1% | 253 | $19K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 890 | $19K |
| 74019 | <1% | 90 | $18K | |
| 83735 | <1% | 3,685 | $18K | |
| 94729 | <1% | 98 | $18K | |
| 77072 | <1% | 167 | $17K | |
| 83021 | <1% | 1,049 | $17K | |
| 73140 | <1% | 185 | $17K | |
| 82785 | <1% | 1,267 | $16K | |
| 86140 | <1% | 3,295 | $16K | |
| 0001A | <1% | 752 | $16K | |
| 95716 | <1% | 18 | $15K | |
| 85045 | <1% | 4,005 | $14K | |
| 86408 | <1% | 459 | $14K | |
| 87807 | <1% | 1,035 | $13K | |
| 86038 | <1% | 1,208 | $13K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 181 | $13K |
| 11900 | <1% | 39 | $12K | |
| 96910 | <1% | 177 | $12K | |
| 90378 | <1% | 41 | $12K | |
| 92579 | <1% | 105 | $11K | |
| 90474 | <1% | 1,632 | $11K | |
| 83615 | <1% | 1,904 | $11K | |
| 84100 | <1% | 2,761 | $11K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 68 | $11K |
| 84146 | <1% | 733 | $11K | |
| 92550 | <1% | 98 | $10K | |
| 82248 | <1% | 2,339 | $10K | |
| 92586 | <1% | 34 | $10K | |
| 95819 | <1% | 36 | $8K | |
| 93225 | <1% | 99 | $8K | |
| 90686 | <1% | 3,175 | $8K | |
| 83970 | <1% | 229 | $8K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 87 | $7K |
| 73562 | <1% | 46 | $7K | |
| 81001 | <1% | 2,690 | $7K | |
| 87070 | <1% | 857 | $7K | |
| 73110 | <1% | 59 | $7K | |
| 69210 | <1% | 115 | $7K | |
| 86039 | <1% | 623 | $7K | |
| 95700 | <1% | 28 | $6K | |
| 29075 | <1% | 116 | $6K | |
| 31526 | <1% | 34 | $6K | |
| 95714 | <1% | 13 | $6K | |
| 85027 | <1% | 1,018 | $6K | |
| 85652 | <1% | 2,317 | $6K | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 86 | $6K |
| 82570 | <1% | 1,061 | $5K | |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 91 | $5K |
| 86812 | <1% | 538 | $5K | |
| 80197 | <1% | 589 | $5K | |
| 84403 | <1% | 219 | $5K | |
| 85576 | <1% | 279 | $4K | |
| 81229 | <1% | 44 | $4K | |
| 83525 | <1% | 384 | $4K | |
| 36591 | <1% | 79 | $4K | |
| 90674 | <1% | 394 | $4K | |
| 73130 | <1% | 56 | $4K | |
| 84681 | <1% | 288 | $3K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 10,703 | $3K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 167 | $3K |
| 82043 | <1% | 563 | $3K | |
| 92582 | <1% | 30 | $3K | |
| 86800 | <1% | 180 | $3K | |
| G0433 | Infectious agent antibody detection by enzyme-linked immunosorbent assay (elisa) technique, hiv-1 and/or hiv-2, screening | <1% | 432 | $3K |
| 92285 | <1% | 26 | $3K | |
| 77073 | <1% | 18 | $3K | |
| 80076 | <1% | 218 | $3K | |
| 86431 | <1% | 477 | $3K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,838 | $2K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 231 | $2K |
| 85730 | <1% | 507 | $2K | |
| 83540 | <1% | 441 | $2K | |
| 90670 | <1% | 3,164 | $2K | |
| 73080 | <1% | 16 | $2K | |
| 64643 | <1% | 659 | $2K | |
| 86376 | <1% | 149 | $2K | |
| 0296T | <1% | 12 | $2K | |
| 86160 | <1% | 138 | $2K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 39 | $2K |
| 81002 | <1% | 755 | $2K | |
| V5264 | Ear mold/insert, not disposable, any type | <1% | 27 | $2K |
| 92555 | <1% | 44 | $2K | |
| 0082A | <1% | 55 | $2K | |
| 84466 | <1% | 137 | $2K | |
| 92651 | <1% | 13 | $2K | |
| 86592 | <1% | 541 | $2K | |
| 92552 | <1% | 12 | $2K | |
| 90651 | <1% | 496 | $1K | |
| 86225 | <1% | 132 | $1K | |
| V5266 | Battery for use in hearing device | <1% | 151 | $1K |
| 85610 | <1% | 379 | $1K | |
| 0081A | <1% | 55 | $1K | |
| 85046 | <1% | 174 | $1K | |
| 84156 | <1% | 313 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,057 | $1K |
| 82977 | <1% | 185 | $1K | |
| 83001 | <1% | 67 | $1K | |
| 84305 | <1% | 59 | $987.52 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 207 | $958.79 |
| 00126 | <1% | 131 | $856.93 | |
| 83002 | <1% | 51 | $851.92 | |
| 93296 | <1% | 16 | $755.40 | |
| 87088 | <1% | 99 | $737.97 | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 90 | $704.68 |
| 82670 | <1% | 28 | $698.54 | |
| 92201 | <1% | 22 | $661.54 | |
| 82962 | <1% | 190 | $632.89 | |
| 83690 | <1% | 144 | $620.30 | |
| 87799 | <1% | 23 | $618.50 | |
| 88738 | <1% | 148 | $609.44 | |
| 87077 | <1% | 55 | $567.81 | |
| 83520 | <1% | 13 | $546.44 | |
| 85651 | <1% | 163 | $543.40 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 180 | $521.97 |
| 76000 | <1% | 12 | $512.50 | |
| 82139 | <1% | 27 | $468.50 | |
| G9035 | Oseltamivir phosphate, oral, brand, per 75 mg (for use in a medicare-approved demonstration project) | <1% | 12 | $438.41 |
| 86256 | <1% | 35 | $430.72 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,764 | $395.67 |
| 82310 | <1% | 75 | $390.14 | |
| 85007 | <1% | 155 | $380.96 | |
| J2704 | Injection, propofol, 10 mg | <1% | 529 | $360.98 |
| 87186 | <1% | 45 | $346.96 | |
| 90734 | <1% | 355 | $303.17 | |
| A6222 | Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 69 | $301.94 |
| 82390 | <1% | 28 | $298.25 | |
| 87205 | <1% | 76 | $294.63 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 33 | $277.29 |
| 83789 | <1% | 13 | $265.21 | |
| 82373 | <1% | 27 | $263.75 | |
| 86430 | <1% | 52 | $259.07 | |
| 91307 | <1% | 2,147 | $249.95 | |
| 83918 | <1% | 13 | $246.24 | |
| 82261 | <1% | 14 | $243.62 | |
| 86364 | <1% | 52 | $242.20 | |
| 36416 | <1% | 130 | $238.21 | |
| 82017 | <1% | 13 | $224.88 | |
| 82379 | <1% | 13 | $224.88 | |
| 90715 | <1% | 110 | $211.10 | |
| 82947 | <1% | 59 | $208.98 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 13 | $203.25 |
| 90661 | <1% | 23 | $201.40 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 387 | $197.38 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 929 | $185.47 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,515 | $174.29 |
| 87040 | <1% | 16 | $165.12 | |
| 83516 | <1% | 16 | $161.42 | |
| 87270 | <1% | 14 | $155.74 | |
| 82805 | <1% | 17 | $143.39 | |
| 97802 | <1% | 13 | $140.10 | |
| 83605 | <1% | 12 | $130.57 | |
| 99442 | <1% | 21 | $129.48 | |
| 90633 | <1% | 1,040 | $127.51 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 13 | $125.07 |
| 0358T | <1% | 16 | $117.36 | |
| 87184 | <1% | 39 | $82.28 | |
| 99173 | <1% | 236 | $79.50 | |
| J3490 | Unclassified drugs | <1% | 519 | $66.00 |
| Q0169 | Promethazine hydrochloride, 12.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 26 | $65.23 |
| 83550 | <1% | 13 | $61.18 | |
| 88720 | <1% | 12 | $57.15 | |
| 88342 | <1% | 262 | $52.18 | |
| 84035 | <1% | 13 | $43.56 | |
| 88304 | <1% | 362 | $35.09 | |
| 90685 | <1% | 676 | $26.79 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 365 | $23.73 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 231 | $19.71 |
| 90744 | <1% | 225 | $19.49 | |
| B4082 | Nasogastric tubing without stylet | <1% | 235 | $17.28 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 214 | $17.21 |
| 90656 | <1% | 109 | $16.61 | |
| A6258 | Transparent film, sterile, more than 16 sq. in. but less than or equal to 48 sq. in., each dressing | <1% | 330 | $14.64 |
| 99001 | <1% | 3,308 | $14.25 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 205 | $13.53 |
| L3260 | Surgical boot/shoe, each | <1% | 21 | $11.40 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 13 | $9.51 |
| 91300 | <1% | 1,872 | $5.44 | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 425 | $5.30 |
| 95874 | <1% | 201 | $4.90 | |
| A6212 | Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing | <1% | 125 | $4.88 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 248 | $3.76 |
| A6257 | Transparent film, sterile, 16 sq. in. or less, each dressing | <1% | 225 | $3.20 |
| 91308 | <1% | 235 | $0.36 | |
| 90671 | <1% | 77 | $0.01 | |
| 90698 | 0% | 1,668 | $0.00 | |
| 90680 | 0% | 1,148 | $0.00 | |
| 90716 | 0% | 103 | $0.00 | |
| 81374 | 0% | 128 | $0.00 | |
| 88300 | 0% | 90 | $0.00 | |
| 90647 | 0% | 141 | $0.00 | |
| 90743 | 0% | 316 | $0.00 | |
| 90619 | 0% | 18 | $0.00 | |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 358 | $0.00 |
| 64430 | 0% | 24 | $0.00 | |
| 90723 | 0% | 129 | $0.00 | |
| J0586 | Injection, abobotulinumtoxina, 5 units | 0% | 34 | $0.00 |
| 91305 | 0% | 16 | $0.00 | |
| 99174 | 0% | 37 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 24 | $0.00 |
| 99417 | Prolong home eval add 15m | 0% | 50 | $0.00 |
| 90697 | 0% | 19 | $0.00 | |
| 90696 | 0% | 25 | $0.00 | |
| L8613 | Ossicula implant | 0% | 44 | $0.00 |
| 90681 | 0% | 57 | $0.00 | |
| 90707 | 0% | 92 | $0.00 | |
| 00920 | 0% | 32 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 72 | $0.00 |
| 90700 | 0% | 12 | $0.00 | |
| 90648 | 0% | 12 | $0.00 | |
| 81243 | 0% | 14 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 16 | $0.00 |
| 90710 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFRAGOUSO, LUCIO (CFO)
| Provider | Location | Paid |
|---|---|---|
| Children's Hospital | New Orleans, LA | $24.37M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.